Indirect Allorecognition of Mismatched Donor HLA Class II Peptides in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome

American Journal of Transplantation

Volumn 1, Issue 3, 2001, Pages 228-235

  Reznik, Scott I ^a   Jaramillo, Andrés ^a   Sivasai, Krovvidi S R ^a   Womer, Karl L ^b   Sayegh, Mohamed H ^b   Trulock, Elbert P ^a   Patterson, G Alexander ^a   Mohanakumar, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CD4 T cells; Chronic rejection; Indirect allorecognition; Lung

Indexed keywords

ALLOANTIBODY; HLA D ANTIGEN; HLA DR ANTIGEN; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ARTICLE; BLOOD; BRONCHIOLITIS OBLITERANS; CHEMISTRY; FOLLOW UP; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; LUNG TRANSPLANTATION; MOLECULAR GENETICS; PATHOLOGY; POSTOPERATIVE COMPLICATION; T LYMPHOCYTE; TIME;

AMINO ACID SEQUENCE; BRONCHIOLITIS OBLITERANS; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY TESTING; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; ISOANTIBODIES; LUNG TRANSPLANTATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0035453247     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2001.001003228.x     Document Type: Article

References (46)

1. Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI. Are multiple immunopathogenic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation 1993; 55: 1040-1044.
2. Kelly K, Hertz MI. Obliterative bronchiolitis. Clin Chest Med 1997; 18: 319-338.
3. Tullius SG, Tilney NL. Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313-318.
4. Allen MD, Burke CM, McGregor CGA, Baldwin JC, Jamieson SW, Theodore J. Steroid-responsive bronchiolitis after human heart-lung transplantation. J Thorac Cardiovasc Surg 1986; 92: 449-451.
5. Glanville AR, Baldwin JC, Burke CMTJ, Robin ED. Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Intern Med 1987; 107: 300-304.
6. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195-202.
7. Yousem SA, Dauber JA, Keenan R, Paradis IL, Zeevi A, Griffith BP. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? Transplantation 1991; 52: 306-309.
8. Sundaresan SR, Mohanakumar T, Smith MA et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648-653.
9. Smith MA, Sundaresan SR, Mohanakumar T et al. Effect of development of antibodies to HLA and CMV mismatch on lung transplant survival and development of bronchiolitis obliterans syndrome. Am J Thorac Surg 1998; 116: 812-820.
10. Jaramillo A, Smith MA, Phelan D et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155-1161.
11. SivaSai KSR, Smith MA, Poindexter N et al. Indirect recognition of donor HLA class I peptides in lung transplantation recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67: 1094-1098.
12. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-38.
13. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen. The role of peptides. Transplantation 1994; 57: 1295-1302.
14. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Ann Rev Immunol 1993; 11: 385-402.
15. Watschinger B, Gallon L, Carpenter C, Sayegh MH. Mechanism of allo-recognition. Recognition by in vivo primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994; 57: 572-576.
16. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB. The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation 1995; 59: 612-616.
17. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699-703.
18. Suciu-Foca N, Reed E, D'Agati VD et al. Soluble HLA antigens, anti-HLA antibodies and anti-idiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593-601.
19. Liu Z, Sun YK, Xi YP et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177: 1643-1650.
20. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H Jr. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865-872.
21. Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Int Rev Immunol 1996; 13: 221-229.
22. Parker KE, Dalchau R, Fowler VJ, Priestley CA, Carter CA, Fabre JW. Stimulation of CD4+ T lymphocytes by allogeneic MHC peptides presented on autologous antigen presenting cells. Transplantation 1992; 53: 918-924.
23. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci 1992; 89: 7762-7766.
24. Liu Z, Colovai AI, Tugulea S et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150-1157.
25. Liu Z, Harris PE, Coloval AI, Reed EF, Maffei A, Suciu-Foca. N. Indirect recognition of donor MHC class II antigens in human transplantation. Clin Immunol Immunopathol 1996; 78: 228-235.
26. Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64: 795-800.
27. Waaga AM, Chandraker A, Spadafora-Ferreira M et al. Mechanisms of indirect allorecognition. Characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation 1998; 65: 876-883.
28. Clubotariu R, Liu Z, Colovai AI et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Inv 1998; 101: 398-405.
29. Taylor PM, Rose ML, Yacomb MH. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. Transplantation 1989; 48: 506-510.
30. Milne DS, Gascoigne AD, Wilkes J et al. MHC class II and ICAM-I expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 1994; 57: 1762-1766.
31. Yousem SA, Curley JM, Dauber J et al. HLA-class II antigen expression in human heart-lung allografts. Transplantation 1990; 49: 991-995.
32. Smith CR, Jaramillo A, Duffy BF, Mohanakumar T. Airway epithelial cell damage mediated by antigen-specific T cells: implications in lung allograft rejection. Hum Immunol 2000; 61: 985-992.
33. Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12: 713-716.
34. Dozmorov I, Eisenbraun MD, Lefkovits I. Limiting dilution analysis: from frequencies to cellular interactions. Immunol Today 2000; 21: 15-18.
35. deWaal MR, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
36. Murphy B, Magee CC, Alexander SI et al. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest 1999; 103: 859-867.
37. Lechler RI, Lombardi G, Batchelor JR. The molecular basis of alloreactivity. Immunol Today 1990; 11: 83-88.
38. Lechler RI, Heaton T, Barber L, Ball V, Batchelor JR, Lombardi G. Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses. Immunol Lett 1992; 34: 63-70.
39. Benichou G, Tam RC, Soares L, Fedoseyeva EV. Indirect T cell allorecognition: perspectives for peptide-based therapy in transplantation. Immunol Today 1997; 18: 67-71.
40. Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992; 175: 305-308.
41. Benham AM, Sawyer GJ, Fabre JW. Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation 1995; 59: 1028-1032.
42. Sawyer GJ, Dalchau R, Fabre JW. Indirect T cell allorecognition: a cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens. Transplant Immunol 1993; 146: 972.
43. Clerici M, Shearer GM. Differential sensitivity of human T, helper cell pathways by in vitro exposure to cyclosporin A. J Immunol 1990; 144: 2480-2485.
44. Benichou G, Fedoseyeva EV. The contribution of peptides to T cell allorecognition and allograft rejection. Int Rev Immunol 1996; 13: 231-243.
45. Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119: 39-45.
46. Kresnsky AM, Clayberger C. HLA-derived peptides as novel immunotherapeutics. Clin Immunol Immunopathol 1995; 75: 112-116.